Result of GM and Completion of Placing

RNS Number : 3855Y

Evgen Pharma PLC

08 May 2019

 

Evgen Pharma plc

("Evgen" or the "Company")

Result of GM

and

Completion of Placing

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that at the Company's General Meeting held earlier today, all of the resolutions tabled at the meeting were duly passed.

As a result, the Company is pleased to announce that it expects the remaining 20,275,840 Placing Shares in the Company, to be admitted to trading on the AIM market of the London Stock Exchange on 9 May 2019. This completes the Placing to raise £5 million at a price of 15 pence per Ordinary Share, as announced on 17 April 2019. 

Total Voting Rights

Following admission of the remaining Placing Shares the total voting rights in the Company will be 132,324,663. The figure of 132,324,663 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Company's announcement released on 17 April 2019.

For further information please contact:       

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com	[phone]
WG Partners LLP Nigel Barnes, Claes Spång	[phone]
Buchanan Mark Court, Sophie Wills, Tilly Abraham [e-mail]	[phone]

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com  

 

END

 

 

ROMLLFFIEDITIIA